Hughes Medical Institute Spreads Its Riches Far And Wide

“I didn’t need to think about the offer very long,” Tjian says with a laugh, recalling his initial shock. HHMI was offering to bankroll Tjian’s research on DNA transcription for a minimum of seven years, and possibly for the rest of his career. And he wasn’t the only one. As the nation’s largest private sponsor of biomedical research, the institute spent about $200 million last year supporting senior investigators like Tjian. After becoming a Hughes Instit

| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

“I didn’t need to think about the offer very long,” Tjian says with a laugh, recalling his initial shock. HHMI was offering to bankroll Tjian’s research on DNA transcription for a minimum of seven years, and possibly for the rest of his career. And he wasn’t the only one. As the nation’s largest private sponsor of biomedical research, the institute spent about $200 million last year supporting senior investigators like Tjian.

After becoming a Hughes Institute investigator, Tjian relinquished many of his federal and outside grants. But he hasn’t missed the weeks of proposal writing and red tape. ‘It’s cut down on my headaches a lot,” he says about his new source of funding. “I feel I’m in a privileged situations”

Many scientists have heard—and fantasized—about the institute’s generosity toward its researchers. But until recently HHMJ investigators belonged to distinct research groups at medical centers. Five years ago Howard Hughes ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies